The recent $175 million investment in Korsana Biosciences highlights a powerful trend in Alzheimer’s disease (AD) research: growing confidence that incremental advances in biology can drive meaningful improvements in safety, tolerability, and efficacy for disease-modifying therapies.
As the anti-amyloid field matures, venture capital and strategic investors are increasingly recognizing that “second-generation” approaches may unlock greater clinical benefit while addressing some of the limitations of first-wave therapies.
The Promise of Second-Generation Anti-Amyloid Therapies
Next-generation anti-amyloid antibodies aim to build on early successes by:
- More effectively clearing pathogenic protein aggregates
- Enhancing the potential for durable clinical benefit
- Reducing treatment-associated risks, including ARIA (Amyloid-Related Imaging Abnormalities)
ARIA, manifesting as brain swelling (ARIA-E) or microbleeds (ARIA-H), are typically asymptomatic but can present serious safety concerns and require careful monitoring. These risks may limit the broader adoption of first-generation agents, particularly among vulnerable populations and amid ongoing pressures on healthcare utilization.
Notably, risk factors for ARIA — including advanced age, APOE ε4 status, hypertension, anticoagulant use, and pre-existing microhemorrhages — all closely mirror the characteristics of the AD population itself. This underscores the importance of therapies designed with improved safety profiles from the outset.
Informed Perspective Through Deep Clinical Experience
Our perspective on these developments is grounded in decades of experience in neurodegenerative disease research, including monoclonal antibodies targeting:
- Amyloid-β
- Tau
- α-synuclein
In addition, our long-standing clinical partnership with Eisai on the leqembi® (lecanemab-irmb) program has provided firsthand insight into the operational, regulatory, and patient-centered considerations shaping this evolving therapeutic class.
This depth of experience enables us to support innovators as they refine next-generation approaches and navigate complex development pathways.
Why Investment in Neurodegenerative Disease Matters
AD remains one of the most significant unmet medical needs in global healthcare. The World Health Organization ranks dementia as the seventh leading cause of death globally, with more than 55 million people currently living with the condition.
As populations age, the prevalence of cognitive decline and neurodegenerative disease will continue to rise. This places increasing strain on families, healthcare systems, and societies.
Sustained investment in emerging biopharma is essential to advancing breakthrough innovation that can meaningfully change patient outcomes. Supporting the next wave of scientific progress today lays the foundation for more effective, accessible therapies tomorrow.
Looking Ahead
The continued evolution of anti-amyloid therapies reflects both scientific progress and growing confidence in the future of AD research. As second-generation programs advance, the focus on improving safety, tolerability, and real-world impact will be critical to expanding patient access and long-term success.
We are encouraged by the momentum in this space and remain committed to partnering with innovators who are translating promising biology into life-changing treatments for patients and their families.
